NextCure (NXTC) Stock: Buy, Sell, or Hold?
NXTC - NextCure, Inc. Common Stock
$5.72
0.49 (9.38%)
â˛
5d:
+5.06%
30d:
+12.5%
90d:
+13.84%
WAIT
LOW Confidence
Analysis Updated: Oct 27, 2026 12:00 AM ET
Earnings: Nov 04, 2026
6d
Get Alerted When NXTC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: NXTC is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: NXTC is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: NXTC is currently trading at $5.71, which is considered fair relative to its 30-day fair value range of $4.90 to $6.35.
Technical Outlook: Technically, NXTC is in a strong uptrend. Immediate support is located at $4.53, while resistance sits at $7.22. The stock is showing strong short-term momentum, up 9.4% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $20.00 (+250.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NXTC is in a strong uptrend. Immediate support is located at $4.53, while resistance sits at $7.22. The stock is showing strong short-term momentum, up 9.4% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $20.00 (+250.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.90 -
$6.35
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.4%)
- BULLISH: Trading 250.0% below Wall St target ($20.00)
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.90 -
$6.35
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$4.53
Resistance Level
$7.22
Current Trend
Strong Uptrend
Technical data as of
Oct 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.97
Wall Street Target
$20.00
(+250.0%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 28, 2026 1:42 AM ET
Data refreshes hourly during market hours. Next update: 2:42 AM
Data refreshes hourly during market hours. Next update: 2:42 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NXTC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
GPCR
Structure Therapeutics IâĻ |
STRONG BUY
16 analysts |
$107 | 59 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 65 BUY |
|
ABVX
Abivax SA American DeposâĻ |
STRONG BUY
12 analysts |
$164 | 69 BUY |
